Insider Purchases: Inside the Buy
Tag: dividend stocks
🐾 Zoetis (ZTS): A Premium Veterinary Titan Sitting in the Doghouse
Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?
🚰 Primo Brands (PRMB): CEO Buys $2M Dip as an $800M Free Cash Flow Giant Emerges 💧⚡
Primo Brands isn't simply selling bottled water.
It's quietly building one of North America's largest hydration infrastructure platforms.
With repeat CEO insider buying, nearly $800 million in annual free cash flow, raised guidance, and exceptional institutional ownership, PRMB deserves a closer look.
💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock
Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.
🌾 Bunge (BG): Why This Agribusiness Compounder Looks Attractive Again After a 43% Rally
Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.
🧪 Huntsman (HUN): CEO Buys $981K as Wall Street Overlooks a $12 Billion Chemical Merger
Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.
🥫 The Great Canned-Good Reset: Inside Conagra's Dividend Cut, Brase's $510K Skin-in-the-Game, and the 10x Forward P/E Floor
Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.
🛢️ Occidental Petroleum (OXY) Stock Analysis: Warren Buffett's Favorite Oil Bet Just Got Even More Interesting
Is Occidental Petroleum one of the market's most misunderstood value stocks? With Warren Buffett owning more than a quarter of the company, a brand-new CEO buying shares, $7.1 billion of debt retired, and a carbon-capture business quietly emerging, OXY may be much more than just another oil producer.
🎢 Six Flags Entertainment (FUN): The 116% Phantom Float Monopoly, Rehan Jaffer's $5.8M Ride, and the 7-Day Short Burn
Six Flags may be more than a roller coaster stock. Insider buying, season-pass growth, improving EBITDA and an unusual ownership structure make FUN one of the more fascinating turnaround stories in leisure.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🧠 Cognizant (CTSH): The Impossible Float Monopoly, Project Leap, and a 9x Multiple GARP Arbitrage
Cognizant may be one of the market's most overlooked AI transformation stories. Strong bookings, aggressive buybacks, and a surprisingly cheap valuation suggest investors may be pricing the company too pessimistically.